Search...
Xintian Pharma: Xinlikang capsules approved to conduct clinical trials for the treatment of cancer-related fatigue
I'm PortAI, I can summarize articles.
According to the Zhitong Finance APP, Xintian Pharma announced that the company recently received the "Drug Clinical Trial Approval Notice" for Xinlikang capsules issued by the National Medical Products Administration, approving the clinical trial for "treatment of cancer-related fatigue."
According to the Zhitong Finance APP, Xintian Pharma (002873.SZ) announced that the company recently received the "Drug Clinical Trial Approval Notice" for Xinlikang capsules issued by the National Medical Products Administration, approving the clinical trial for "the treatment of cancer-related fatigue."
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments